间变型淋巴瘤激酶融合基因与非小细胞肺癌的治疗

Anaplastic lymphoma kinase fusion gene in non-small cell lung cancer

在非小细胞肺癌的治疗中,继表皮生长因子受体(EGFR)基因突变之后,间变型淋巴瘤激酶(ALK)融合基因作为特异性酪氨酸激酶抑制剂的靶点也成为研究热点。美国食品药品管理局(FDA)已于2011年批准克唑替尼用于ALK融合基因阳性非小细胞肺癌患者的治疗,但耐药是影响长期生存的主要问题。本文综述ALK融合基因的形成机制,ALK融合基因阳性非小细胞肺癌患者的检测和治疗现状。

Among various treatments of non-small cell lung cancer,anaplastic lymphoma kinase（ALK） fusion gene draws much attention of oncology professionals as a specific target of tyrosine kinase inhibitors.United States Food and Drug Administration has approved the application of crizotinib for treating non-small cell lung cancer patients whose ALK were tested to be recombinated since 2011.The resistance has been widely recognized as one of the major concern affecting the long term outcome of non-small cell lung cancer patients.This article reviews the formation of ALK fusion gene,the molecular mechanism of the inhibitory effect of crizotinib to c-Met and ALK,the test and treatment of eligible patients.